Madopar HBS and the decompensated phase of Parkinson disease

T. Caraceni, N. Nordera, E. Lamperti, A. Lorizio

Research output: Contribution to journalArticlepeer-review


The most important current problem in the treatment of Parkinson disease in the so-called L-dopa long-term-treatment syndrome. We present here the results of our experience with Madopar HBS in the treatment of two groups of patients suffering from L-dopa long-term treatment syndrome. In the first study we replaced the standard Madopar with Madopar HBS. In the second study, after identifying the most disabling "off" periods, we added Madopar HBS to the previous treatment in such a way as to control these "off" phases. Our study suggests that Madopar HBS is useful in reducing typical fluctuation phenomena in the majority of patients.

Original languageEnglish
Pages (from-to)407-414
Number of pages8
JournalItalian Journal of Neurological Sciences
Issue number4
Publication statusPublished - Aug 1989


  • decompensated phase
  • Madopar HBS
  • Parkinson disease

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Madopar HBS and the decompensated phase of Parkinson disease'. Together they form a unique fingerprint.

Cite this